Navigation Links
InVitria Reveals Technology to Optimize Hybridoma Production Performance
Date:4/22/2009

Article in Spring edition of Bioprocessing Journal reports InVitria's recombinant human serum albumin (Cellastim) and recombinant lactoferrin (Lacromin) cell culture supplements optimize cell growth and productivity in hybridoma cells.

Fort Collins, CO (PRWEB) April 22, 2009-- Recent studies using both classical media and the leading commercial serum-free hybridoma media formulations proved that InVitria's cell culture supplements optimized cell growth and productivity of hybridoma cells.1 Further, the studies revealed that Cellastim supports cell adaptation and survival in chemically-defined media.

Additional findings from the study showed that Cellastim improved the cell growth and productivity in long-term culture. In a 25-day period, cell doublings in Cellastim-supplemented media were twice that of media without Cellastim. Also, antibody production was 65% higher in the commercial media with Cellastim while cells supplemented with Cellastim grew to higher density than those in unsupplemented media.

"This research incorporated classical media as well as several leading commercial media available on the market," said Dr. Steve Pettit, the project's lead researcher. "We achieved optimal cell density and quicker doubling times as well as better cell productivity when Cellastim was added to these media. We also reported that Lacromin improves hybridoma cell culture performance."

Lacromin increased cell density in supplemented media nearly double compared to that of media without Lacromin supplementation. A significant increase in antibody production was recognized in all Lacromin-treated media, exceeding the level achieved with 5% fetal bovine serum (FBS).

"This research supports what customers have been reporting from their use of Cellastim and Lacromin for hybridoma cell culture," said InVitria President and CEO Scott Deeter. "Cellastim has been shown to not only optimize hybridoma performance, but also outperform other sources of native and recombinant albumin."

To obtain a copy of the above-mentioned article entitled, "Enhanced Growth and Productivity of a Hybridoma with Recombinant Human Albumin and Lactoferrin," please contact InVitria at info(at)InVitria(dot)com or 1-800-916-8311.

About InVitria
InVitria develops, manufactures and markets a portfolio of high performance and well defined cell culture products and reagents used in bioprocessing, biopharmaceutical formulation, stem cell & regenerative medicine, life science research and diagnostics.

1Pettit S, Santos M, Tanner T, Huang N. Enhanced Growth and Productivity of a Hybridoma with Recombinant Human Albumin and Lactoferrin. BioProcessing Journal 2009; 8(1): 50-55.

###

Read the full story at http://www.prweb.com/releases/hybridomacells/hybridomaproduction/prweb2350604.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. InVitria Headlines Sponsorship of WilBio's Waterside Conference
2. InVitria Announces Launch of Recombinant Albumin for Diagnostics
3. InVitria's Cell Culture Media Components Showcased at WilBio's 2008 Cell Engineering Meeting
4. InVitria's Cellastim Delivers Superior Results in CHO Cell Culture
5. InVitria to Launch "BE FREE" Promotion at TERMIS '08 in San Diego
6. InVitria to Showcase its Innovative Cell Culture Components at American Society of Cell Biology Annual Meeting
7. InVitria to Present at WilBio's International Cell Engineering Meeting
8. Retirement Living TV Reveals: Sex Is The Real Fountain of Youth
9. New American Lung Association Report Reveals States Failing to Enact Lifesaving Tobacco Control Policies
10. New Research Reveals Need for Doctors to Know About Medical Tattoos
11. Study Reveals How Salmonella Hijacks Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are ... cessation in breathing. Oral appliances can offer significant relief to about 75 percent ...
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
(Date:10/12/2017)... ... 12, 2017 , ... The American College of Medical Informatics (ACMI) will present ... the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium ... Collen, a pioneer in the field of medical informatics, this prestigious award is presented ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
(Date:10/12/2017)... ... 12, 2017 , ... HMP , a leader in healthcare events and ... Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie ... annual award competition recognizes editorial and design excellence across a range of sectors. This ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... , Sept. 25, 2017   Montrium , ... File solutions, today—from the IQPC Trial Master Files ... , NL)—announced that EastHORN Clinical Services has selected ... programs and TMF management. EastHORN, a leading European ... platform to increase transparency to enable greater collaboration ...
(Date:9/19/2017)... Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses ... today:   ... Jim ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and business ...
(Date:9/12/2017)... 12, 2017   EcoVadis , the leading platform for environmental, social ... annual edition of its Global CSR Risk and Performance Index. The report ... based on Scorecard Ratings that analyzed nearly 800,000 data points across the ... ... ...
Breaking Medicine Technology: